Abstract
Within the first 30 years after cancer diagnosis, survivors of childhood cancers have an estimated 75% cumulative incidence of treatment-related chronic health problems. In the United States, where 1 in 680 people between 20 and 50 years old are survivors of childhood cancer, the impact of long-term health consequences is concerning, particularly because this population is growing. Cancer treatment-related cardiotoxicity is the leading noncancer cause of morbidity, and after 30 years, exceeds the mortality rates of cancer recurrence. Cumulative anthracycline chemotherapy dose received is one of the major risk factors. Others include female sex, younger age at diagnosis, and now emerging genetic mutations. However, evidence-based guidelines to identify and monitor cardiotoxicity are lacking. Dexrazoxane provides cardioprotective benefits in children with high-risk cancers, but additional preventive strategies are still needed. An improved understanding of the lifetime cardiovascular risk associated with these factors in long-term childhood cancer survivors may help guide treatment and predict any potential additional cardiovascular risk of specific cancer therapies, such as anthracyclines.
| Original language | English (US) |
|---|---|
| Title of host publication | Cardio-Oncology |
| Subtitle of host publication | Principles, Prevention and Management |
| Publisher | Elsevier Inc. |
| Pages | 173-186 |
| Number of pages | 14 |
| ISBN (Electronic) | 9780128035535 |
| ISBN (Print) | 9780128035474 |
| DOIs | |
| State | Published - Dec 15 2016 |
| Externally published | Yes |
Fingerprint
Keywords
- Cancer treatment
- Cardiac late effects
- Cardiotoxicity
- Childhood cancer survivors
- Dexrazoxane
ASJC Scopus subject areas
- Medicine(all)
Cite this
Late Cardiac Effects in Childhood Cancer Survivors. / Lipshultz, Steven E; Patel, N.; Franco, V. I.; Fisher, S.
Cardio-Oncology: Principles, Prevention and Management. Elsevier Inc., 2016. p. 173-186.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Late Cardiac Effects in Childhood Cancer Survivors
AU - Lipshultz, Steven E
AU - Patel, N.
AU - Franco, V. I.
AU - Fisher, S.
PY - 2016/12/15
Y1 - 2016/12/15
N2 - Within the first 30 years after cancer diagnosis, survivors of childhood cancers have an estimated 75% cumulative incidence of treatment-related chronic health problems. In the United States, where 1 in 680 people between 20 and 50 years old are survivors of childhood cancer, the impact of long-term health consequences is concerning, particularly because this population is growing. Cancer treatment-related cardiotoxicity is the leading noncancer cause of morbidity, and after 30 years, exceeds the mortality rates of cancer recurrence. Cumulative anthracycline chemotherapy dose received is one of the major risk factors. Others include female sex, younger age at diagnosis, and now emerging genetic mutations. However, evidence-based guidelines to identify and monitor cardiotoxicity are lacking. Dexrazoxane provides cardioprotective benefits in children with high-risk cancers, but additional preventive strategies are still needed. An improved understanding of the lifetime cardiovascular risk associated with these factors in long-term childhood cancer survivors may help guide treatment and predict any potential additional cardiovascular risk of specific cancer therapies, such as anthracyclines.
AB - Within the first 30 years after cancer diagnosis, survivors of childhood cancers have an estimated 75% cumulative incidence of treatment-related chronic health problems. In the United States, where 1 in 680 people between 20 and 50 years old are survivors of childhood cancer, the impact of long-term health consequences is concerning, particularly because this population is growing. Cancer treatment-related cardiotoxicity is the leading noncancer cause of morbidity, and after 30 years, exceeds the mortality rates of cancer recurrence. Cumulative anthracycline chemotherapy dose received is one of the major risk factors. Others include female sex, younger age at diagnosis, and now emerging genetic mutations. However, evidence-based guidelines to identify and monitor cardiotoxicity are lacking. Dexrazoxane provides cardioprotective benefits in children with high-risk cancers, but additional preventive strategies are still needed. An improved understanding of the lifetime cardiovascular risk associated with these factors in long-term childhood cancer survivors may help guide treatment and predict any potential additional cardiovascular risk of specific cancer therapies, such as anthracyclines.
KW - Cancer treatment
KW - Cardiac late effects
KW - Cardiotoxicity
KW - Childhood cancer survivors
KW - Dexrazoxane
UR - http://www.scopus.com/inward/record.url?scp=85022002507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85022002507&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-803547-4.00011-2
DO - 10.1016/B978-0-12-803547-4.00011-2
M3 - Chapter
AN - SCOPUS:85022002507
SN - 9780128035474
SP - 173
EP - 186
BT - Cardio-Oncology
PB - Elsevier Inc.
ER -